Molecular Signatures of Cutaneous Dupilumab Response

Part of paid clinical trials in San Francisco, California.

Sponsor
University of California, San Francisco
Study ID
NCT05858619
Phase
PHASE4
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Dupilumab — DRUG
    dupilumab 600 mg injection initially and then 300 mg every other week

Study Details

This study examines the effect of IL4RA blockade with dupilumab on the immune cells of atopic dermatitis skin lesions.

Key Dates

Start date
Feb 1, 2023
Status verified
Jun 2026
Primary completion
Feb 1, 2028
Completion
Feb 1, 2028

Study Design

Enrollment
15 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: dupilumab treatment
    Treatment with IL4RA inhibitor

Primary Outcome Measure

Change in Eczema Area and Severity Index (EASI) score from baseline to 8-12 weeks [ Time Frame: baseline and 8-12 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of California, San FranciscoSan FranciscoCalifornia94143
Jeffrey Cheng, MD, PhD
[email protected]

Find similar trials in San Francisco, CA

By condition
Atopic dermatitis / eczema
By specialty
DermatologyRheumatologyAutoimmune disease
By research site
University of California, San Francisco· San Francisco, CA

Related Studies